Key result
Zacopride, a moderate IK1 channel agonist, exerts antiarrhythmic effects without reported proarrhythmic risks, though it is not suggested in short QT syndrome or reentry tachycardia.
Why the study?
Does zacopride exert proarrhythmic effects in clinical and experimental settings?
Does zacopride exert proarrhythmic effects in clinical and experimental settings?
While zacopride generally lacks reported proarrhythmic effects, caution is advised in specific conditions like short QT syndrome and certain reentry tachycardias.
Zacopride may warrant cautious investigation as an IK1-targeted antiarrhythmic; leaves open prospective validation excluding short QT syndrome and reentry tachycardias.
Zacopride, an IK1 agonist with moderate potency, could exert significant antiarrhythmic and cardiac protective effects. To date, there is no report to show that zacopride is proarrhythmic in both experimental studies and clinical trials. However, in certain cardiac pathological conditions, especially short QT syndrome and certain reentry tachycardia, zacopride is not suggested. Further studies are needed to precisely evaluate the potential arrhythmogenic risk of zacopride.
No takes yet. Share an insight, caveat, or question.
Wu et al. (2014) conducted a review in Short QT syndrome and reentry tachycardia. Zacopride was evaluated. Zacopride, a moderate IK1 channel agonist, exerts antiarrhythmic effects without reported proarrhythmic risks, though it is not suggested in short QT syndrome or reentry tachycardia.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: